March 2023 | Statement
The FDA announced today that an advisory committee meeting is scheduled for May 9 and 10 to review the first-ever application for an over-the-counter birth control pill. In July 2022, HRA Pharma announced it had submitted this application to the FDA to switch Opill, a progestin-only, daily birth...